Bristol Myers' (BMY) Krazati Gets FDA Nod for Colorectal Cancer

Bristol Myers Squibb (BMY) announced that the FDA has approved a label expansion of its oncology drug Krazati (adagrasib).The FDA granted accelerated approval to Krazati, in combination with Erbitux (cetuximab), as a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer (CRC).The FDA’s approval for this indication was on an accelerated basis, based on objective response rate (ORR) and duration of response (DOR) results. Continued approval for thi ...